.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
US Department of Justice
Queensland Health
Colorcon
Federal Trade Commission
McKinsey
Deloitte
Accenture
McKesson
Dow

Generated: September 26, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Treatment of adrenal malfunction
Abstract:Dextrorotatory .alpha.-(4-aminophenyl)-.alpha.-lower alkylglutarimides or salts thereof normalize the secretion of malfunctioning adrenal glands.
Inventor(s): Dziemian; Robert (Cedar Knolls, NJ), Finch; Neville (West Orange, NJ)
Assignee: Ciba-Geigy Corporation (Ardsley, NY)
Application Number:05/396,969
Patent Claims: 1. A pharmaceutical composition for reducing adrenal hyperfunction, comprising an adrenal secretion reducing amount of the dextrorotatory antipode of an .alpha.-(4-aminophenyl)-.alpha.-lower alkylglutarimide or a therapeutically acceptable acid addition salt thereof, and a pharmaceutical excipient.

2. A composition as claimed in claim 1, wherein the antipode is d-aminoglutethimide or a therapeutically acceptable acid addition salt thereof.

3. A composition as claimed in claim 2, wherein the antipode is the d-aminoglutethimide d-tartrate.

4. A composition as claimed in claim 2, wherein the antipode is the d-aminoglutethimide monophosphate.

5. A composition as claimed in claim 1, wherein the antipode content is about 10 to 90% by weight.

6. A composition as claimed in claim 5, wherein the antipode content is about 20 to 80% by weight.

7. A composition as claimed in claim 1, containing between about 450 and about 1,000 mg of the antipode per oral unit dosage form.

8. A method of treating a mammal suffering from malfunctioning adrenal glands, which consists in administering to him enterally or parenterally an adrenal secretion reducing amount of the composition claimed in claim 1.

9. A method as claimed in claim 8, wherein the effective amount of the antipode is between about 8 and 80 mg per kilogram body weight per day of treatment.

10. A method as claimed in claim 8, wherein the effective amount of the antipode is between about 10 and 30 mg per kilogram body weight per day of treatment.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
UBS
Argus Health
Cerilliant
McKesson
Baxter
Harvard Business School
Express Scripts
Medtronic
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot